# EDGAR Filing Document

**Accession Number:** 0001661059
**File Stem:** 0001104659-26-023741
**Filing Date:** 2026-3
**Character Count:** 18911
**Document Hash:** 29d94cecb02091c159370fbb7fa11d73
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-023741.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001104659-26-023741

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91004
- **FILM NUMBER:** 26724080

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sofinnova Venture Partners IX, L.P.
- **CENTRAL INDEX KEY:** 0001612133

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-681-8420

**MAIL ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

## Ex-99.A

<u>exhibit A</u>

<u>Agreement of Joint Filing</u>

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of NextCure, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

Date: May 16, 2019

---

| | |
|:---|:---|
| SOFINNOVA VENTURE PARTNERS IX, L.P., <br> a Delaware Limited Partnership | SOFINNOVA VENTURE PARTNERS IX, L.P., <br> a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT IX, L.L.C., <br> a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT IX, L.L.C., | SOFINNOVA MANAGEMENT IX, L.L.C., |
| a Delaware Limited Liability Company | a Delaware Limited Liability Company |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| DR. JAMES I. HEALY | DR. JAMES I. HEALY |
| DR. MICHAEL F. POWELL | DR. MICHAEL F. POWELL |
| DR. ANAND MEHRA | DR. ANAND MEHRA |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |

---

## Ex-99.B

<u>exhibit B</u>

**<u>Power of Attorney</u>**

Nathalie Auber has signed this Schedule 13D as Attorney-In-Fact. Note that copies of the applicable Power of Attorney are already on file with the appropriate agencies.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**NextCure, Inc.**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**65343E207**

*(CUSIP Number)*

**Nathalie Auber**<br>Sofinnova Investments, Inc.<br>3000 Sand Hill Road, Bldg 3, Suite 150<br>Menlo Park CA 94025<br>(650) 681-8420

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **65343E207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Venture Partners IX, L.P. ("SVP IX")** | Name of reporting person<br>**Sofinnova Venture Partners IX, L.P. ("SVP IX")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: Sofinnova Management IX, L.L.C. ("SM IX"), the general partner of SVP IX, may be deemed to have sole voting power, and Dr. James I. Healy ("Healy"), the managing member of SM IX, may be deemed to have sole power to vote these shares.

Note to Row 8: See response to Row 7.

Note to Row 9: SM IX, the general partner of SVP IX, may be deemed to have sole dispositive power and Healy, the managing member of SM IX, may be deemed to have sole power to dispose of these shares.

Note to Row 10: See response to Row 9.

| **CUSIP No.** | **65343E207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management IX, L.L.C. ("SM IX")** | Name of reporting person<br>**Sofinnova Management IX, L.L.C. ("SM IX")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to Row 7: All shares are owned directly by SVP IX. SM IX, the general partner of SVP IX, may be deemed to have sole voting power, and Healy, the managing member of SM IX, may be deemed to have sole voting power to vote these shares.

Note to Row 8: See response to Row 7.

Note to Row 9: All shares are owned directly by SVP IX.  SM IX, the general partner of SVP IX, may be deemed to have sole dispositive power, and Healy, the managing member of SM IX, may be deemed to have sole dispositive power over these shares.

Note to Row 10: See response to Row 9.

| **CUSIP No.** | **65343E207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**222654.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | Aggregate amount beneficially owned by each reporting person<br>**222654.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 7: All shares are owned directly by SVP IX. SM IX, the general partner of SVP IX, may be deemed to have sole voting power, and Healy, the managing member of SM IX, may be deemed to have sole voting power to vote these shares.

Note to Row 8: See response to Row 7.

Note to Row 9: All shares are owned directly by SVP IX. SM IX, the general partner of SVP IX, may be deemed to have sole dispositive power, and Healy, the managing member of SM IX, may be deemed to have sole power to dispose of these shares.

Note to Row 10: See response to Row 9.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
NextCure, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
9000 Virginia Manor Road, Suite 200, Beltsville, MD, 20705

This Amendment No. 2 ("Amendment No. 2") amends and restates the Statement on Schedule 13D that was originally filed on May 17, 2019 and amended on November 22, 2019 (as amended, the "Original Schedule 13D"). This Amendment No. 2 relates to the beneficial ownership of Common Stock, $0.001 par value per share ("Common Stock") of NextCure, Inc., a Delaware corporation ("Issuer") and is being filed by Sofinnova Venture Partners IX, L.P., a Delaware limited partnership ("SVP IX"), Sofinnova Management IX, L.L.C., a Delaware limited liability company ("SM IX"), and Dr. James I. Healy ("Healy" and collectively with SVP IX, and SM IX, the "Reporting Persons"). This Amendment No. 2 is being filed to update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's additional sales of Common Stock from time to time since the date of the filing of the Original Schedule 13D. The Issuer reported outstanding Common Stock in the Issuer's Form 424(b)(5) filed with the Securities and Exchange Commission on December 19, 2025 (File No. 333-273723) (the "Prospectus Supplement"), causing a decrease in the aggregate percentage ownership by the Reporting Persons of one percent (1%) or more from the percentages reported in the Original Schedule 13D.

(a)      The class of equity securities to which this statement relates is the Common Stock of the Issuer.

(b)      The Issuer's principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.

**Item 4. Purpose of Transaction**

The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 3,122,143 shares of Common Stock outstanding as of December 19, 2025, as reported by the Issuer in the Prospectus Supplement.

**(b)**
Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

**(c)**
Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

SVP IX is a party to the Investors' Rights Agreement among the Issuer, SVP IX and other shareholders. Subject to the terms of such Investors' Rights Agreement, SVP IX can demand that the Issuer file a registration statement or request that its Common Stock be covered by a registration statement that the Issuer is otherwise filing under certain specified circumstances. Such Investors' Rights Agreement dated as of November 5, 2018 is more fully described in the IPO Prospectus and was filed as Exhibit 4.1 to the Issuer's Form S-1 Registration Statement (File No. File No. 333-230837), and such description is incorporated herein by reference.

In connection with the IPO Offering, SVP IX and certain other holders of shares of Common Stock have entered into Lock-Up Agreements with the Issuer's underwriters or otherwise agreed, subject to certain exceptions, that they will not, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale, or otherwise dispose of or hedge any of shares of Common Stock, any options or warrants to purchase shares of Common Stock, or any securities convertible into, or exchangeable for or that represent the right to receive shares of Common Stock, without the prior written consent of the representatives of the Issuer's underwriters for a period of 180 days from the date of the IPO Prospectus. Such Lock-Up Agreement is more fully described in the IPO Prospectus and was filed as Exhibit A of Exhibit 1.1 to the Issuer's Form S-1 Registration Statement (File No. 333-230837), and such description is incorporated herein by reference.

In connection with the Follow-On Offering, SVP IX and certain other holders of shares of Common Stock have entered into Lock-Up Agreements with the Issuer's underwriters or otherwise agreed, subject to certain exceptions, that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, without the prior written consent of the representatives of the Issuer's underwriters for a period of 90 days from the date of the Follow-On Prospectus. Such Lock-Up Agreement is more fully described in the Follow-On Prospectus and was filed as Exhibit A of Exhibit 1.1 to the Issuer's Form S-1 Registration Statement (File No. 333-234639), and such description is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Venture Partners IX, L.P. ("SVP IX")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management IX, L.L.C. ("SM IX")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. James I. Healy ("Healy")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026